Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Andecaliximab Monotherapy and Combination Therapy in Japanese Gastric/GEJ Adenocarcinoma
NCT02862535Phase 1Terminated
- Sponsor
- Gilead Sciences
- Start
- Sep 2016
- Primary completion
- Oct 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of andecaliximab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (4 arms), sponsored by Gilead Sciences. Primary endpoints: Percentage of Participants Experiencing Treatment-Emergent Adverse Events up to 82.4 weeks and Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities up to 82.4 weeks. Started Sep 2016; status: terminated.
02
Drugs
andecaliximab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT02862535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02862535.